title: Allopurinol and mortality in hyperuricaemic patients.
abstract: OBJECTIVE
  While studies have suggested that gout and hyperuricaemia are associated with the risk of premature death, none has investigated the role of urate-lowering therapy on this critical outcome. We examined the impact of allopurinol, the most commonly used urate-lowering drug, on the risk of mortality in hyperuricaemic patients.
  
  
  METHODS
  From a population of hyperuricaemic veterans of [serum urate level >416 micromol/l (7.0 mg/dl)] at least 40 years of age, we compared the risk of death between incident allopurinol users (n = 2483) and non-users (n = 7441). We estimated the multivariate mortality hazard ratio (HR) of allopurinol use with Cox proportional hazards models.
  
  
  RESULTS
  Of the 9924 veterans (males, 98% and mean age 62.7 years), 1021 died during the follow-up. Patients who began treatment with allopurinol had worse prognostic factors for mortality, including higher BMI and comorbidities. After adjusting for baseline urate levels, allopurinol treatment was associated with a lower risk of all-cause mortality (HR 0.78; 95% CI 0.67, 0.91). Further adjustment with other prognostic factors did not appreciably alter this estimate (HR 0.77; 95% CI 0.65, 0.91). The mean change from baseline in serum urate within the allopurinol group was -111 micromol/l (-1.86 mg/dl). Adjusting for baseline urate level, allopurinol users had a 40 micromol/l (0.68 mg/dl) lower follow-up serum urate value than controls (95% CI -0.55, -0.81).
  
  
  CONCLUSIONS
  Our findings indicate that allopurinol treatment may provide a survival benefit among patients with hyperuricaemia.
authors.affiliation: Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle, WA, USA.
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Luk
authors.forename: Gregory P
authors.initials: GP
authors.lastname: Levin
authors.forename: Elya E
authors.initials: EE
authors.lastname: Moore
authors.forename: Xiao-Hua
authors.initials: XH
authors.lastname: Zhou
authors.forename: Bryan R
authors.initials: BR
authors.lastname: Kestenbaum
authors.forename: Hyon K
authors.initials: HK
authors.lastname: Choi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000493:Allopurinol / Q000627:therapeutic use*; D016022:Case-Control Studies; D005260:Female; D005500:Follow-Up Studies; D006073:Gout / Q000188:drug therapy / Q000401:mortality; D006074:Gout Suppressants / Q000627:therapeutic use*; D006801:Humans; D033461:Hyperuricemia / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014728:Veterans
chemical_list: D006074:Gout Suppressants; D000493:Allopurinol